Gut bacteria and CDK4/6 inhibitor treatment in breast cancer
Part of Cancer, Skin clinical trials.
This study looks at how gut bacteria affect response to a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy in breast cancer that is hormone receptor-positive and HER2-negative. It may help find out why some people respond better to treatment and could lead to better personalized care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hormone receptor-positive (HR+), HER2-negative breast cancer that has spread or is at high risk of coming back.
- You are about to start a CDK4/6 inhibitor combined with hormone therapy as your first treatment for advanced cancer, or as an additional treatment after surgery for early cancer at high risk.
- You are 18 years or older and can provide a sample of your tumor tissue (or that tissue is already available).
- You have not started the CDK4/6 inhibitor yet, and you have not taken oral or IV antibiotics in the last month.
- You do not have HIV, hepatitis C, active hepatitis, inflammatory bowel disease, or a malabsorption condition, and you drink less than 3 glasses of alcohol per day.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well CDK4/6 inhibitors combined with hormone therapy work in real-world settings for people with a certain type of advanced breast cancer (HR+/HER2-). It aims to understand the best treatment path and what happens next.
This study looks at how well CDK4/6 inhibitors (a type of targeted therapy) work in real-world patients with HR+/HER2- advanced breast cancer. By collecting medical data from people treated at this hospital, doctors hope to learn more about the effectiveness and safety of these drugs in everyday practice.
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
This trial studies how CDK4/6 medicines fit into treatment for people with advanced hormone receptor–positive breast cancer that cannot be cured with surgery or radiation. It may help doctors understand the best way to use these medicines for disease that has returned or spread.
This trial is for people with a common type of breast cancer that is hormone-receptor-positive and HER2-negative, and has a high risk of coming back. It looks at how well patients take a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy after surgery, to help prevent recurrence.
This trial tests whether adding a CDK4/6 inhibitor (a type of targeted pill) to standard hormone therapy after surgery can lower the risk of breast cancer coming back in women with high-risk, hormone-receptor-positive, HER2-positive early breast cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.